Countries with millions of hepatitis C cases could help leapfrog sales of a next-generation pan-genotype therapy under development by AbbVie.
Sanofi provided insight into the logistics hurdles faced by vaccine makers in China after a distribution and sales rule changed.
Sales in Venezuela came to a standstill for Merck in the second quarter as the country's economy sinks into a deeper crisis on food and medicines.
Bristol-Myers Squibb gave a second-quarter figure on the contribution it gets from Japan-related sales via a development and commercialization partnership with…
Hutchison China MediTech has accelerated and expanded work on c-MET inhibitor candidate savolitinib through an amended license deal with AstraZeneca.
Amgen's Bob Bradway, chairman and CEO, cited a recent deal with Daiichi Sankyo in Japan as key for biosimilar sales in the country.
COPD sales in China for AstraZeneca will remain strong as the number of nebulizer centers expands in the country.
GlaxoSmithKline has cautioned that a weaker pound after the Brexit vote has raised some liabilities even as it gained on repatriating cash flows from abroad.
Takeda Pharmaceutical said it would accelerate a reorganization of its R&D units in the U.S. and Japan to focus on the three therapy areas previously…
Astellas Pharma said core profit reached ¥67.1 billion in the first quarter, up a tad more than 49%.